<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494154</url>
  </required_header>
  <id_info>
    <org_study_id>IUCPQ-HDWOBPT</org_study_id>
    <nct_id>NCT02494154</nct_id>
  </id_info>
  <brief_title>Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Patients.</brief_title>
  <acronym>HDWOBPT</acronym>
  <official_title>Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the work of breathing among patients under various conditions of
      treatment with high flow nasal cannulas. Sixteen spontaneously breathing patients with
      respiratory failure (hypercapnic or hypoxemic) will be included. The design of this study is
      a cross over of four treatment periods with different flow settings.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High flow oxygen therapy (HFOT) is a promising technique increasingly used in the management
      of acute respiratory failure. In hospitalised hypoxemic patients, recent clinical evidence
      showed that HFOT can reduce endotracheal intubation and reduce mortality. Physiologically,
      the HFOT causes a decrease in respiratory rate and minute-ventilation and may be associated
      with a decrease in PaCO2. It is possible that these effects are associated with decreased
      work of breathing, which could explain some of the benefits in terms of comfort and
      efficiency.

      The objective of this research is to evaluate the impact of a wash-out of anatomical dead
      space by high flow nasal cannulas on respiratory parameters and on the work of breathing.

      The investigators will evaluate the baseline status with conventional oxygen therapy methods
      (low flows), and then compare it with three different levels of high flow oxygen therapy in a
      randomised order. The primary endpoint will be the work of breathing.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Work of breathing</measure>
    <time_frame>15 minutes</time_frame>
    <description>Work of breathing at the end of each period is calculated from the measurement of esophageal pressure and tidal volume (composite outcome)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Esophageal pressure-time product</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tidal volume</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comfort of breathing</measure>
    <time_frame>15 minutes</time_frame>
    <description>Subjective evaluation at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood gases</measure>
    <time_frame>15 minutes</time_frame>
    <description>Arterial or capillary blood gases at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>15 minutes</time_frame>
    <description>Evaluation on a borg scale at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-tidal carbon dioxide</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>15 minutes</time_frame>
    <description>Measured at the end of each period</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Conventional flow via nasal prongs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxygen delivery via conventional nasal interface with flow adjusted to reach a target SpO2 according to the patient's condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High flow nasal cannulas 20L/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen delivery via high flow nasal cannulas (20L/min) with fraction of inspired oxygen (FiO2) adjusted to reach a target SpO2 according to the patient's condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High flow nasal cannulas 40L/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen delivery via high flow nasal cannulas (40L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High flow nasal cannulas 60L/min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen delivery via high flow nasal cannulas (60L/min) with FiO2 adjusted to reach a target SpO2 according to the patient's condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Airvo 2; Ficher and Paykel HealthCare</intervention_name>
    <description>High flow nasal cannulas</description>
    <arm_group_label>High flow nasal cannulas 20L/min</arm_group_label>
    <arm_group_label>High flow nasal cannulas 40L/min</arm_group_label>
    <arm_group_label>High flow nasal cannulas 60L/min</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Oxygen delivery via conventional nasal mask</intervention_name>
    <description>Low flow of oxygen delivered through conventional nasal prongs</description>
    <arm_group_label>Conventional flow via nasal prongs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Spontaneously breathing patients exhibiting a respiratory distress defined by a respiratory
        rate ≥ 20 breaths/min associated with

          -  either hypoxemia (SpO2&lt;90% with O2≥3L/min) ;

          -  or hypercapnia (PaCO2&gt;45 mmHg with a respiratory acidosis (pH&lt;7,38).

        Exclusion Criteria:

          -  Patients below 18yo, pregnant or breastfeeding women;

          -  Patients enrolled in another study excluding co-enrolment;

          -  History of ear nose and throat disease (i.e. surgery, epistaxis, trauma), eso-gastric
             disease (i.e. esophageal varices, digestive haemorrhage), rheumatologic or neurologic
             disease possibly interfering with the design of the study;

          -  Acute respiratory or cardiovascular disease contra-indicating the enrolment in the
             study protocol (i.e. acute coronary syndrome, pulmonary embolism, pneumothorax);

          -  Need for immediate intubation or for continuous noninvasive ventilation and/or recent
             (&lt;6h) arterial blood gases showing a respiratory acidosis with a pH&lt;7.30;

          -  Patient feeling nauseous or under recent fed condition (&lt;1h).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Lellouche, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>IUCPQ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathieu Delorme, PT, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3508</phone_ext>
    <email>mathieu.delorme.2@ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François Lellouche, MD, PhD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3298</phone_ext>
    <email>francois.lellouche@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Lellouche, MD, PhD</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3298</phone_ext>
      <email>francois.lellouche@criucpq.ulaval.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>July 9, 2015</last_update_submitted>
  <last_update_submitted_qc>July 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

